Q1 2023 Earnings Estimate for PetMed Express, Inc. Issued By Jefferies Financial Group (NASDAQ:PETS)

PetMed Express, Inc. (NASDAQ:PETSGet Rating) – Investment analysts at Jefferies Financial Group decreased their Q1 2023 earnings per share estimates for shares of PetMed Express in a research note issued to investors on Tuesday, May 10th. Jefferies Financial Group analyst S. Wissink now anticipates that the company will post earnings of $0.30 per share for the quarter, down from their previous estimate of $0.33. Jefferies Financial Group also issued estimates for PetMed Express’ Q2 2023 earnings at $0.29 EPS, Q3 2023 earnings at $0.21 EPS, Q4 2023 earnings at $0.23 EPS, FY2023 earnings at $1.04 EPS and FY2024 earnings at $1.10 EPS.

PetMed Express (NASDAQ:PETSGet Rating) last issued its quarterly earnings data on Monday, May 9th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.27 by $0.03. PetMed Express had a net margin of 7.83% and a return on equity of 16.00%. During the same quarter in the prior year, the business earned $0.34 earnings per share.

Several other research firms have also recently issued reports on PETS. Sidoti raised PetMed Express from a “neutral” rating to a “buy” rating and set a $32.00 target price on the stock in a research note on Thursday, January 20th. Morgan Stanley reduced their price objective on shares of PetMed Express from $25.00 to $21.00 and set an “underweight” rating on the stock in a research report on Tuesday, January 25th. StockNews.com initiated coverage on shares of PetMed Express in a research report on Thursday, March 31st. They issued a “hold” rating for the company. Finally, Zacks Investment Research cut shares of PetMed Express from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $27.00.

PETS opened at $22.22 on Wednesday. PetMed Express has a one year low of $19.65 and a one year high of $46.67. The business has a 50 day simple moving average of $25.30 and a two-hundred day simple moving average of $26.21. The firm has a market capitalization of $466.15 million, a price-to-earnings ratio of 20.57 and a beta of 0.55.

The company also recently declared a quarterly dividend, which will be paid on Friday, May 27th. Investors of record on Friday, May 20th will be paid a $0.30 dividend. The ex-dividend date of this dividend is Thursday, May 19th. This represents a $1.20 annualized dividend and a yield of 5.40%. PetMed Express’s payout ratio is 111.11%.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of PetMed Express by 46.3% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 546,352 shares of the company’s stock valued at $14,096,000 after buying an additional 173,030 shares in the last quarter. Gagnon Securities LLC boosted its stake in PetMed Express by 3.7% during the first quarter. Gagnon Securities LLC now owns 20,074 shares of the company’s stock worth $518,000 after acquiring an additional 709 shares in the last quarter. Swiss National Bank grew its holdings in PetMed Express by 11.0% in the first quarter. Swiss National Bank now owns 49,600 shares of the company’s stock worth $1,280,000 after purchasing an additional 4,900 shares during the period. Fisher Asset Management LLC increased its stake in shares of PetMed Express by 46.3% during the first quarter. Fisher Asset Management LLC now owns 128,683 shares of the company’s stock valued at $3,320,000 after purchasing an additional 40,748 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of PetMed Express by 40.0% during the first quarter. Russell Investments Group Ltd. now owns 6,738 shares of the company’s stock valued at $173,000 after purchasing an additional 1,924 shares during the last quarter. Institutional investors and hedge funds own 80.95% of the company’s stock.

About PetMed Express (Get Rating)

PetMed Express, Inc, together with its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.

See Also

Earnings History and Estimates for PetMed Express (NASDAQ:PETS)

Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.